In the first half of 2020 (H1), the U.S. is anticipated to account for the largest share of in-vitro diagnostics industry followed by Europe. This owes primarily to the ongoing marketing of innovative diagnostic products associated with ongoing advances in the field of gene & immunoassay based products, the latest discovery of genetic biomarkers and their clinical significance in immunoassay testing, favorable government policies and their emphasis on the development of new products, and the significant expansion of target population.
The need of immunoassay kit for reliable COVID 19 test led the country’s government to reduce the price of these tests, so that individual belonging to any economic status can afford such tests.
COVID-19 convalescent plasma has not yet been approved by the FDA, to it is regulated as an exploratory product. As such, the COVID-19 administration convalescent plasma by a physician must be under investigation by a new drug application (IND) under traditional regulatory through IND, Extended Access IND, or newly announced administration of a new emergency drug (eIND) for one patient (42) U.S.C. 262(a)(3); 21 U.S.C. 355(i); 21 CFR 601.21; and 21 CFR 312.1). The FDA is not doing collection of COVID-19 convalescent plasma or provides COVID-19 convalescent plasma. Healthcare professionals or acute care facilities would receive COVID-19 instead convalescent plasma from an FDA-registered blood establishment.
Wearables technology products have been accepted well in the consumer medical tech field but the healthcare industry has questioned their utility beyond heart rate tracking and for more crucial applications of healthcare. This means that the market was limited to consumers and healthcare providers till now.
Many countries are involved in manufacturing of PPE products. Among which, China is the largest producer. According to the UNICEF, China produces approximately 50% of global surgical masks. Other countries include Taiwan which produces around 20% of global supply of face masks alone followed by India, Mexico, U.S., Japan, Malaysia, Korea, European countries, and others.
Plasma medications are produced from human blood plasma (plasma). Plasma can be obtained from administration of whole blood (recovered plasma) or apheresis procedures (plasma source). The source is plasma a wide range of medicinal therapies products used for treatment and the prevention of various treatment-causing injuries and diseases often associated with a protein deficiency state. Convalescent Plasma Therapy (CP), a classic adaptive immunotherapy, has been used in the prevention and treatment of many infectious diseases for over a century. In the past two decades, CP therapy has been successfully used in the treatment of the 2009 SARS, MERS and H1N1 pandemic with satisfactory efficacy and safety. In 2014, the World Health...
COVID-19 outbreak has also made healthcare professionals to look for alternative methods to traditional systems and processes. This is leading an expedited adoption of mHealth across the industry both from providers and consumers.
COVID-19 has largely forced several countries to impose different types of lockups on their citizens, although conditions vary from country to country. India and China are among the few countries that eliminated several potential committees that affected several markets and their economies.